search

Active clinical trials for "Ovarian Hyperstimulation Syndrome"

Results 61-63 of 63

Study of Serum Levels of Oxidative Stress Markers in Ovarian Hyperstimulation Patients

Ovarian Hyperstimulation Syndrome

The aim of the study is to determine serum oxidative stress status by ischemia modified albumin (IMA), total antioxidant capacity (TAC), total oxidative capacity (TOS), oxidative stress capacity (OSI), and serum malondialdehyde (MDA) in patients with OHHS and control group. We also aim to reveal the association between serum levels of these factors and oocyte quality.

Unknown status7 enrollment criteria

Long Acting GnRH Antagonist in PCOS Women Undergoing IVF

Polycystic Ovarian SyndromeOvarian Hyperstimulation Syndrome1 more

PCOS is a common endocrinopathy affecting 5-10% of women in their reproductive age characterized by hyperandrogenism, chronic anovulation and polycystic ovaries. This syndrome is a serious problem in IVF since there is a high risk of developing ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation with gonadotropins. The introduction of GnRH antagonist in IVF has reduced the incidence of severe OHSS, still maintaining a good ovarian response and pregnancy rate. Recently, a long acting GnRH antagonist, Degarelix, was introduced for prostatic cancer treatment. Furthermore a recent paper reported its use also for the induction of multiple follicular growth in a program of oocyte donation. The aim of this study is to evaluate the feasibility of GnRH antagonist depot use in a protocol of controlled ovarian hyperstimulation in PCOS women at risk of developing OHSS in IVF cycles.

Unknown status6 enrollment criteria

Monitoring the Early Follicular Phase With Androstenedione in Low-dose Step-up Ovulation Induction...

InfertilityOvarian Hyperstimulation Syndrome

This study aims to predefine the threshold FSH doses during the early follicular phases in low- dose step-up ovulation induction cycles used to treat anticipated high responders by monitoring total testosterone and androstenedione blood levels. The blood levels of total testosterone and androstenedione levels will be measured in patients at the starting day and at every control day when vaginal sonographic folliculometries and blood estradiol measurements are made. Hence, we are aiming to define an early monitoring parameter by which we will be able to define a follicular response to treatment before estradiol rise or apparently selected follicular growth.

Unknown status15 enrollment criteria
1...67

Need Help? Contact our team!


We'll reach out to this number within 24 hrs